For outpatients with influenza infection, oseltamivir is not associated with a reduced risk for hospitalization, according to a review published online June 12 in JAMA Internal Medicine.
Jun 14, 2023
0
2
A Europe-wide study conducted over three flu seasons finds that the antiviral drug, oseltamivir (Tamiflu), can help people recover from flu-like illness about one-day sooner on average, with older, sicker patients who have ...
Dec 20, 2019
0
32
Researchers at the University of Oxford have found that placebo controls are almost never described according to standard reporting guidelines.
Sep 30, 2019
0
2
In an editorial published today, Mark Ebell, Professor of Epidemiology at the University of Georgia, outlines important lessons from the Tamiflu story.
Jul 13, 2017
0
7
Earlier this month, the Centers for Disease Control and Prevention recommended the use of antiviral drugs to help treat influenza, in a year when the available vaccine is not a good match for the current strain.
Jan 29, 2015
0
92
(HealthDay)—Oseltamivir and zanamivir reduce the time to symptomatic improvement in influenza by about half a day, but evidence to support claims of reduced admissions to hospital or complications of influenza is lacking, ...
Apr 10, 2014
0
0
(HealthDay)—As soon as the updated seasonal flu vaccine becomes available, parents should bring children aged 6 months and older to get vaccinated, according to an updated policy statement from the American Academy of Pediatrics ...
Sep 2, 2013
0
0
Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, ...
Jul 16, 2013
0
0
Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomised ...
May 30, 2013
0
0
Laboratory tests have revealed resistance in some H7N9 bird flu patients to the only available treatment, said virologists who unveiled "concerning" study results on Tuesday.
May 28, 2013
0
0
Oseltamivir INN ( /ɒsəlˈtæmɨvɪər/), an antiviral drug, slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell; median time to symptom alleviation is reduced by 0.5–1 day. The drug is sold under the trade name Tamiflu, and is taken orally in capsules or as a suspension. It has been used to treat and prevent influenza A virus and influenza B virus infection in over 50 million people since 1999.[citation needed]
Oseltamivir is a prodrug, a (relatively) inactive chemical which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed.[citation needed] It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is currently marketed by Hoffmann–La Roche (Roche). In Japan, it is marketed by Chugai Pharmaceutical Co., which is more than 50% owned by Roche.
As of December 2010[update], the World Health Organization (WHO) reported 314 samples of the prevalent 2009 pandemic H1N1 flu tested worldwide have shown resistance to oseltamivir.
This text uses material from Wikipedia, licensed under CC BY-SA
